Tavexia Lifecare Q2 Results, Acquisition Funding, and RTA Change
Sattva Sukun Lifecare Ltd · Financial Result · 05 Nov 2026, 3:03 am
Tavexia Lifecare Q2 Results, Acquisition Funding, and RTA Change Tavexia Lifecare's board approved Q2 un-audited results for the period ended 30th Sep'26, reporting consolidated revenue from operations of ₹503.94 lakhs compared to ₹1,684.33 lakhs YoY, with a net loss of ₹40.12 lakhs versus a net profit of ₹78.21 lakhs in the prior-year quarter. Standalone net loss stood at ₹51.40 lakhs. The board granted in-principle approval to raise up to ₹68 crore via securities issuance to finance its proposed 60% stake acquisition in Meyonex Pharmaceuticals. Additionally, RTA operations will transition from Niche Technologies to Skyline Financial Services.
Original exchange filing (PDF)
More announcements from Sattva Sukun Lifecare Ltd
- Financial Result · 05 Nov 2026
- Announcement · 05 Nov 2026
- Board has Approved in Change in RTA · 05 Nov 2026
- Outcome of Board Meeting · 05 Nov 2026
- Tavexia Lifecare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve Intimation of Board Meeting · 04 Nov 2026
- Announcement · 13 Oct 2026
- Disclosure under regulation 30 · 12 Oct 2026
- Disclosure under regulation 30 · 08 Oct 2026
